|
|
|
|
|
Metaraminol
drug data and news
Metaraminol drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Metaraminol | ||
| Brand Names/Synonyms | Aramine; HSDB 2716; Hydroxynorephedrine; Icoral B; L-Metaraminol; M-Hydroxy Norephedrine; M-Hydroxyphenylpropanolamine; M-Hydroxypropadrine; METARAMINOL; Metaradrine; Metaraminol; Metaraminol Bitartrate; Metaraminolum [Inn-Latin]; Metaraminolum [Latin]; Pressonex; Pressorol | ||
| Indication | For the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Metaraminol is a potent sympathomimetic amine that increases both systolic and diastolic blood pressure. Metaraminol is indicated for prevention and treatment of the acute hypotensive state occurring with spinal anesthesia. It is also indicated as adjunctive treatment of hypotension due to hemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to trauma or tumor. Metaraminol acts on both α1-adrenergic receptors but appears to have no effect on β-adrenergic receptors. It acts by increasing the force of the heart's pumping action as well as constricting peripheral blood vessels. | ||
| Mechanism Of Action | Metaraminol acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic & diastolic). Its effect is thought to be associated with the inhibition of adenyl cyclase which leads to an inhibition of the production of cAMP. Another effect of Metaraminol is that it releases norepinephrine from its storage sites indirectly. | ||
| Metaraminol News (When available) |
| ||
| Dosage Forms | Intramuscular injection; Intravenous injection | ||
| Drug_Category | Adrenergic Agents; Adrenergic alpha-Agonists; Sympathomimetics; Vasoconstrictor Agents; ATC:C01CA09 | ||
| Absorption | The effect starts 1-2 min after IV injection, 10 min after IM injection, 5-20 min after subcutaneous injection. | ||
| Interactions |
Interactions for Metaraminol: ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias. Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines. Therefore, when initiating pressor therapy in patients receiving these drugs, the initial dose should be small and given with caution. | ||
| Toxicity | LD50=240 mg/kg (rat, oral); LD50=99 mg/kg (mouse, oral) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 3-(2-amino-1-hydroxy-propyl)phenol | ||
| Chemical Formula | C9H13NO2 | ||
| Molecular Weight | 167.205 g/mol | ||
| Smiles String | CC(C(C1=CC(=CC=C1)O)O)N | ||
| Melting Point | 107.5 °C | ||
| Water Solubility | 1E+006 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 0.6 | ||
| Isoelectric Point | 8.79 | ||
| Biotransformation | Hepatic | ||
| Half Life | Not Available | ||
| Protein Binding [%] | ~45% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.rxlist.com/cgi/generic2/metar.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00555 | ||
| CAS Registry Number | 54-49-9 | ||
| KEGG Compound ID | C07146 | ||
| PubChem ID | CID:4087 | ||
| PharmGKB ID | PA450392 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |